Sign inJoin waitlistJoin the waitlist

Anne Chiang

Associate Cancer Center Director, Clinical Initiatives · Yale-New Haven Hospital

Credentials: · · · · ·

History

Medical Oncology and Hematology · Yale-New Haven Hospital
Present
Medical Oncology and Hematology · Yale-New Haven Hospital
Present
Medical Oncology and Hematology · Yale School of Medicine
Present

Interventional Cardiology
Baylor College of Medicine
2011–2012
Baylor College of Medicine
2008–2011
Internal Medicine
University of Texas Southwestern Medical Center
2006–2007
Memorial Sloan Kettering Cancer Center
2003–2006
Memorial Sloan Kettering Cancer Center
2004–2006
New York Presbyterian Hospital
2000–2003
New York Presbyterian Hospital Columbia Medical Center
1999–2000
Harvard University
Cornell Univ Joan and Sanford I Weill Med Coll
1995–1999
Harvard University
1992–1995
Princeton University
1984–1987
Princeton University
1987

Research

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
The Lancet Oncology · 2016 · 837 citations
Molecular basis of metastasis
Review · New England Journal of Medicine · 2008 · First of 2 authors · 784 citations
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
Clinical Cancer Research · 2006 · 667 citations

RH
Roy Herbst
9 papers
Scott Gettinger
8 papers
Cary Gross
7 papers · 4 as a resident
Afshin Dowlati
6 papers
Sarah Goldberg
6 papers
Arif Kamal
5 papers
Kerin Adelson
5 papers
Sonam Puri
5 papers
AA
Amy Abernethy
4 papers
KS
Kurt Schalper
4 papers
Lauren Byers
4 papers
Ronald Chen
4 papers

Grants

NCI National Clinical Trials Network (NCTN) - Network Lead Academic Participating Sites
National Cancer Institute · UG1
Contact PI · $2.3M · Yale University
2019–2032

Clinical trials

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Principal investigator · Recruiting · Phase 2
SWOG Cancer Research Network
2025–2029
Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy
Principal investigator · Active not recruiting · Phase 2
Yale University
2018–2025
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
Principal investigator · Withdrawn · Phase 1
Yale University
2018–2019
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2025–2029